

AF
Atty. Docket No.: INGA, 004
2ND Supplemental Information Disclosure Statement
2ND Supplemental IDS filed: May 30, 2006

TFW
1633

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of: CHARLES CONRAD §
Serial No: 09/169,793 § Group Art Unit: 1633
Filed: October 9, 1998 § Examiner: J. Martinell
Title: PRODUCTION OF ssDNA *IN VIVO* § Atty. Docket No: INGA,004

TO:

Commissioner of Patents and Trademarks
PO Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING (37 CFR 1.8a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope, addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450	
<i>Cindee R. Ewell</i>	<i>May 30, 2006</i>
Name: <i>Cindee R. Ewell</i>	Date

SECOND - SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In compliance with Applicant's duty of candor and good faith, Applicant files this 2nd Supplemental Information Disclosure Statement in accordance with the provisions of 37 CFR §§1.97 and 1.98 to make the references listed on the attached disclosure form PTO/SB/08 of record in the captioned application.

Also, in compliance with § 1.97, an information disclosure statement is herein filed within one of the following time periods:

- ☒ (1) the 2nd Supplemental information disclosure statement is filed in the early stages of prosecution:
- ☐ within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
 - ☐ within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
 - ☐ before the mailing of a first Office action on the merits; OR
 - ☒ before the mailing of a first Office action after the filing of a request for continued examination under §1.114;

OR,

- ☐ (2) the information disclosure statement is filed before the mailing date of any of a final action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application, and it is accompanied by ONE OF:

- ☐ A statement as specified under 37 CFR 1.97(e):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement.

OR,

- ☐ The fee set forth in §1.17(p),

OR,

- ☐ (3) the information disclosure statement is filed on or before payment of the issue fee and is accompanied by:

- ☐ The statement specified under 37 CFR 1.97(e);

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

AND,

- ☐ The fee set forth in §1.17(p).

Also, in accordance with the above provisions, please find:

- ☒ A copy of the most recently filed Supplemental Information Disclosure Statement filed May 17, 2006 for this application:

SN 09/169,793 Supp. IDS filed May 17, 2006 (INGA,004) – this application

Applicant hereby respectfully includes this for clarity.

- ☒ A copy of search reports provided by official examining authorities for applications containing similar subject matter which may be material to the patentability of this application.
Additional search reports were generated during Official Examination for the following:

PCT/US99/23936	Filed Oct. 12, 1999	(INGA,004/PCT)
PCT/US00/27381	Filed Oct. 4, 2000	(INGA,004/CIP/PCT)
PCT/US99/23933	Filed Oct. 12, 1999	(CRYA,008/PCT)
EP 99 950 296.6	PCT/US99/23936	(INGA,004/PCT)

Applicant hereby requests consideration of the art cited on the copies provided.

- ☒ A 2nd Supplemental Information Disclosure Statement in accordance with §1.98(a)(1);
- ☒ Legible Copies in accordance with §1.98(a)(2) of:
- (i) each foreign patent;
 - (ii) each publication or that portion which caused it to be listed, other than U.S. patents and U.S. patent application publications unless required by the Office;
 - (iii) for each cited pending unpublished U.S. application, the application specification including the claims, and any drawing of the application, or that portion of the application which caused it to be listed including any claims directed to that portion; and
 - (iv) all other information or that portion which caused it to be listed.
- ☐ In accordance with §1.98(a)(3), for documents not in the English language:
- ☐ a concise explanation of the relevance, as it is presently understood by the individual designated in §1.56(c) most knowledgeable about the content of the information, of each patent, publication, or other information listed that is not in the English language;
- AND,
- ☐ a copy of the translation if a written English-language translation of a non-English-language document, or portion thereof, is within the possession, custody, or control of, or is readily available to any individual designated in §1.56(c).
- ☐ A Check in the amount of the fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §§1.97(c)(2) and 1.97(d)(2).
- ☐ A Revocation of Power of Attorney with New Power of Attorney and Change of Correspondence Address with New Power of Attorney and Change of Correspondence Address
- ☐ A copy of Statement under 37 CFR 3.73(b) and any required accompanying documents.

- ☒ A stamped, self-addressed Postcard acknowledging receipt of this document and the accompanying documents as listed herein above.

Please return the enclosed postcard, properly date stamped, to the undersigned attorney for Applicant upon receipt of the enclosed correspondence.

In the event a check covering the appropriate fee(s) is not enclosed, is unsigned, or is insufficient in amount, or any other mistake is made by Applicant which should incur additional fees, the Commissioner is authorized to charge Deposit Account No: 50-3748 (INGA,004) for the amount of any deficiency.


Respectfully submitted,



Malcolm Skolnick
Reg. No. 33788
CytoGenix, Inc.
3100 Wilcrest Drive, Suite 140
Houston, Texas 77042
TEL: (713) 789-0070
FAX: (713) 789-0702
ATTORNEY FOR APPLICANT

Date: May 26, 2006

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**



Sheet 1 of 1

Application Number: 09/169,793
 Filing Date: Oct. 9, 1998
 First Named Inventor: Charles CONRAD
 Art Unit: 1631 / 1633
 Examiner Name: James Martinell
 Attorney Docket Number: INGA, 004

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code- Number-Kind Code	Publication date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear


NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	AGRAWAL, S., et al., <i>Antisense Research and Application</i> , Chapter 1, pg. 1-50, ed. S. Crooke, Springer-Verlag, 1998.	
	2	BREAKER, R.R., <i>In Vitro Selection of Catalytic Polynucleotides</i> , Chem. Rev., 97: 371-90, 1997	

EXAMINER
SIGNATURE _____

DATE
CONSIDERED _____

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**



Application Number: 09/169,793
 Filing Date: Oct. 9, 1998
 First Named Inventor: Charles CONRAD
 Art Unit: 1631
 Examiner Name: James Martinell
 Attorney Docket Number: INGA, 004

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-5714323	02-1998	OHSHIMA, A., INOUE, et al.	
	2	US-5756291	05-1998	GRIFFIN, et al.	
	3	US-5807718	09-1998	JOYCE, G.F. and BREAKER, R.R.	
	4	US-5503978	04-1999	SCHNEIDER, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code- Number-Kind Code	Publication date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	5	WO-9529993	11/9/95	NABEL, G.J., et al.	


NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	6	BARABINO, S., et al., <i>Antisense probes targeted to an internal domain in U2 snRNP specifically inhibit the second step of pre-Nrma splicing</i> , Nucleic Acids Research, 20 (17): 4457-4464, 1992	
	7	BECK, E., et al., <i>Nucleotide sequence and genome organization of filamentous bacteriophages f1 and fd</i> , Gene, 16: 35, 1981	
	8	BECK, E., et al., <i>Nucleotide sequence of bacteriophage fd DNA</i> , Nucleic Acids Res. 5: 4495, 1978	
	9	BENNETT, et al., <i>Inhibition of Endothelial Cell Adhesion Molecule Expression with Antisense Oligonucleotides</i> , Journal of Immunology, 152: 3530-3540, 1994	
	10	BRANCH, A. Trends in Biochem. Sci., Vol 23, pgs 45-50 (1998)	
	11	CHAN, et al., <i>Triplex DNA: Fundamentals, Advances, and Potential Applications for Gene Therapy</i> , J. Mol. Med., 75: 267-282, 1997	
	12	CLACKSON, <i>Controlling mammalian gene expression with small molecules</i> , Current Opinion in Chemical Biology, 1: 210-218, 1997	
	13	CLEARY, J.M., et al., <i>Replication of the plasmid pBR322 under the control of a cloned replication origin from the single-stranded DNA phage M13</i> , PNAS, 77: 4638, 1980	
	14	CROOKE, S. <i>Antisense Research and Application</i> , Chapter 1, pgs 1-50, Ed. by S. Crook, Publ. by Springer-Verlag (1998)	
	15	DAUM, G., et al., <i>The ins and outs of raf kinases</i> , Trends in Biochemical Sciences, 19: 474-480, 1994	

EXAMINER
SIGNATURE _____

DATE
CONSIDERED _____

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**



Application Number: 09/169,793
 Filing Date: Oct. 9, 1998
 First Named Inventor: Charles CONRAD
 Art Unit: 1631
 Examiner Name: James Martinell
 Attorney Docket Number: INGA, 004

Sheet 1 of 2

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	16	DENTE, L., et al., <i>pEMBL, A new family of single stranded plasmids</i> , Nucleic Acids Res., 11: 1645, 1983	
	17	DHUNDALE, A., et al., <i>Structure of msDNA from Myxococcus xanthus: Evidence for a Long, self-Annealing RNA Precursor for the Covalently Linked, Branched RNA</i> , Cell, 51: 1105-1112, Dec 1987	
	18	DOTTO, G.P., et al., <i>Functional Analysis of Bacteriophage ϕ1 Intergenic Region</i> , Virology, 114: 463-473, 1981	
	19	FOSSE', P., et al., <i>Modified Nucleotides of tRNA^{Pro} Restrict Interactions in the Binary Primer/ Template Complex of M-MuLV</i> , J. Mol. Biol., 275: 731-746, 1998	
	20	HELENE, C. and TOULME, J., <i>Biochim. Biophys. Acta.</i> , 1049: 99-125, 1990	
	21	KIM, K., et al., <i>A Mutational Study of the Site-Specific Cleavage of EC83, a Multicopy Single-Stranded DNA (msDNA): Nucleotides at the msDNA Stem Are Important for Its Cleavage</i> , Journal of Bacteriology, 179(20): 6518-6521, 1997	
	22	KONINGS, R.N.H., et al., <i>Transcription of the filamentous phage genome</i> , The Single-stranded DNA phages (ed. D.T. Denhardt et al.), pp. 507, 1978	
	23	LAMPSON, Bert C., et al., <i>Reverse Transcriptase in a Clinical Strain of Escherichia coli: Production of Branched RNA-Linked msDNA</i> , Research Articles, Science, 243: 1033-38, Feb 1989	
	24	LEVINSON, A., et al., <i>Minimal size plasmids containing and M13 origin for production of single-strand transducing particles</i> , J. Mol. Appl. Genet 2: 507, 1984	
	25	LIEBER, Andre, et al., <i>Selection of Efficient Cleavage Sites in Target RNAs by Using a Ribozyme Expression Library</i> , Molecular and Cellular Biology, 15 (1): 540-551, Jan 1995	
	26	LIMA, Tania M. and Lim, Dongbin, <i>A Novel Retron That Produces RNA-less msDNA in Escherichia coli Using Reverse Transcriptase</i> , Plasmid, 38: 25-33, June 1997	
	27	MAO, Jau-Ren, et al., <i>msDNA-Ec48, the smallest Multicopy Single-Stranded DNA from Escherichia coli</i> , Journal of Bacteriology, 179 (24): 7865-7868, Dec 1997	
	28	MARVIN, D.A., <i>Filamentous bacterial viruses</i> , Bacteriol. Rev., 33:172, 1969	
	29	MEAD, D.A., et al., <i>A universal method for the direct cloning of PCR amplified nucleic acid</i> , Biotechnology, 9: 657, 1991	
	30	MILLER, P.S., <i>Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression</i> , J.S. Cohen (ed.), CRC Press: Boca Raton, pp. 79, 1989	
	31	MIYATA, S., et al., <i>In vivo production of a stable single-stranded cDNA in Saccharomyces cerevisiae by means of a bacterial retron</i> , PNAS, 89: 5735-5739 Biochemistry, July 1992	
	32	NOONBERG, et al., <i>In Vivo Generation of Highly Abundant Sequence-Specific Oligonucleotides for Antisense and Triplex Gene Regulation</i> , Nucleic Acids Res., 22: 2830-2836, 1994	
	33	PEETERS, B.P.H., et al., <i>Plasmid pKUN9, a versatile vector for the selective packaging of both DNA strands into single-stranded DNA-containing phagelike particles</i> , Gene 41: 39, 1986	
	34	PETROPOULOS, C.J., <i>Retroviral taxonomy, protein structure, sequences and genetic maps</i> , J.M Coffin (Ed.), Retroviruses, 757-805, Appendix 2, New York: Cold Springs Harbor Press, 1997	
	35	SANTORO, S.W. and Joyce, G. F., <i>A general purpose RNA-cleaving DNA enzyme</i> , PNAS, 94: 4262-4266, Biochemistry, April 1997	
	36	SANTORO, S.W. and Joyce, G. F., <i>Mechanism and Utility of an RNA-Cleaving DNA Enzyme</i> , Biochemistry, 37 (38): 13330-13342, July 1998	
	37	SEIDMAN, et al. <i>Introduction of Plasmid DNA into Cells</i> , in Current Protocols in Molecular Biology, Unit 1.8 (1997)	
	38	YANISCH-PERRON, C., <i>Improved M13 phage cloning vectors and host strains: Nucleotide sequences of the M13mp18 and pUC19 vectors</i> , Gene 33: 103, 1985	

EXAMINER
SIGNATURE _____

DATE
CONSIDERED _____